| Published Application/Species/Dilution | Reference |
|---|
- immunohistochemistry; mouse; fig 4
| Amato K, Wang S, Tan L, Hastings A, Song W, Lovly C, et al. EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res. 2016;76:305-18 pubmed publisher |
- immunocytochemistry; mouse
- western blot; mouse
| Bantikassegn A, Song X, Politi K. Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomas. Am J Respir Cell Mol Biol. 2015;52:409-17 pubmed publisher |
- immunoprecipitation; human; 1:1000
| Tjin Tham Sjin R, Lee K, Walter A, Dubrovskiy A, Sheets M, Martin T, et al. In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing. Mol Cancer Ther. 2014;13:1468-79 pubmed publisher |
- western blot; human; 1:1000
| Pan T, Sun J, Hu J, Hu Y, Zhou J, Chen Z, et al. Cytohesins/ARNO: the function in colorectal cancer cells. PLoS ONE. 2014;9:e90997 pubmed publisher |
| Houang M, Sioson L, Clarkson A, Watson N, Farzin M, Toon C, et al. EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology. 2014;46:501-8 pubmed publisher |
| Bondgaard A, Høgdall E, Mellemgaard A, Skov B. High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer. Mod Pathol. 2014;27:1590-8 pubmed publisher |
| Soma S, Tsuta K, Takano T, Hatanaka Y, Yoshida A, Suzuki K, et al. Intratumoral distribution of EGFR-amplified and EGFR-mutated cells in pulmonary adenocarcinoma. Pathol Res Pract. 2014;210:155-60 pubmed publisher |
| Wang X, Wang G, Hao Y, Xu Y, Zhang L. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer. Int J Clin Exp Pathol. 2014;7:4310-6 pubmed |
| Kawahara A, Taira T, Abe H, Watari K, Murakami Y, Fukumitsu C, et al. Fixation effect of SurePath preservative fluids using epidermal growth factor receptor mutation-specific antibodies for immunocytochemistry. Cancer Cytopathol. 2014;122:145-52 pubmed publisher |
| Secq V, Villeret J, Fina F, Carmassi M, Carcopino X, Garcia S, et al. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations. Br J Cancer. 2014;110:1045-52 pubmed publisher |
| Baldi L, Mengoli M, Bisagni A, Banzi M, Boni C, Rossi G. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer. 2014;86:291-5 pubmed publisher |
| Jiang G, Fan C, Zhang X, Dong Q, Wang L, Liu Y, et al. Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS ONE. 2013;8:e59183 pubmed publisher |
| Uramoto H, Yamada S, Tanaka F. Angiogenesis of lung cancer utilizes existing blood vessels rather than developing new vessels using signals from carcinogenesis. Anticancer Res. 2013;33:1913-6 pubmed |
| Shiozawa T, Ishii G, Goto K, Nagai K, Mimaki S, Ono S, et al. Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung. Pathol Int. 2013;63:77-84 pubmed publisher |
| Wang Y, Jiang C, Guan J, Yang G, Yue J, Chen H, et al. Molecular alterations of EGFR in small intestinal adenocarcinoma. Int J Colorectal Dis. 2013;28:1329-35 pubmed publisher |
| Ho H, Chang F, Ma H, Liao L, Chuang Y, Chang-Chien Y, et al. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Respirology. 2013;18:1261-70 pubmed publisher |
| Fan X, Liu B, Xu H, Yu B, Shi S, Zhang J, et al. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples. Hum Pathol. 2013;44:1499-507 pubmed publisher |
| Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012;92:371-83 pubmed publisher |
| Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS ONE. 2012;7:e41017 pubmed publisher |
| Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023-8 pubmed publisher |
| Kawahara A, Taira T, Azuma K, Tominaga M, Hattori S, Kawahara M, et al. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer. 2012;78:39-44 pubmed publisher |
| Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, et al. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment. J Thorac Oncol. 2012;7:122-7 pubmed publisher |
| Angulo B, Conde E, Suarez-Gauthier A, Plaza C, Martinez R, Redondo P, et al. A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. PLoS ONE. 2012;7:e43842 pubmed publisher |
| Kim L, Kim K, Yoon Y, Ryu J, Choi S, Park I, et al. Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients. J Korean Med Sci. 2012;27:1027-36 pubmed publisher |
| Simonetti S, Molina M, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, et al. Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med. 2010;8:135 pubmed publisher |
| Tsai T, Wu S, Chang Y, Wu C, Tsai M, Wei P, et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol. 2012;7:993-1000 pubmed publisher |
| Shimamura T, Perera S, Foley K, Sang J, Rodig S, Inoue T, et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012;18:4973-85 pubmed publisher |
| Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12:169-76 pubmed publisher |
| Rimkunas V, Crosby K, Li D, Hu Y, Kelly M, Gu T, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-57 pubmed publisher |
| Ambrosini-Spaltro A, Campanini N, Bortesi B, Azzoni C, Naldi N, Ampollini L, et al. EGFR mutation-specific antibodies in pulmonary adenocarcinoma: a comparison with DNA direct sequencing. Appl Immunohistochem Mol Morphol. 2012;20:356-62 pubmed publisher |
| Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, et al. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res. 2010;16:3163-70 pubmed publisher |
